Hematopoietic Growth Factors in Oncology

1. Front Matter

   Pages i-x

   PDF

2. Basic Research

   1. Front Matter

      Pages 1-1

      PDF

   2. Introduction to Hematopoietic Growth Factors

      • George Morstyn, MaryAnn Foote

      Pages 3-10

   3. Animal Models of Hematopoietic Growth Factor Perturbations in Physiology and Pathology

      • Graham J. Lieschke

      Pages 11-44

   4. The Jak-Stat Pathway of Cytokine Signaling

      • Ben A. Croker, Nicos A. Nicola

      Pages 45-64

   5. Small-Molecule and Peptide Agonists

      • Ellen G. Laber, C. Glenn Begley

      Pages 65-80

3. Hematopoietic Growth Factors

   1. Front Matter

      Pages 81-81

      PDF

   2. Granulocyte Colony-Stimulating Factor

      • Graham Molineux

      Pages 83-95

   3. Erythropoietic Factors

      • Steven Elliott, Anne C. Heatherington, MaryAnn Foote

      Pages 97-123

   4. Thrombopoietin Factors

      • David J. Kuter

      Pages 125-151

   5. Stem Cell Factor and Its Receptor, c-Kit

      • Keith E. Langley

      Pages 153-184

   6. Hematopoietic Growth Factors

      • Ann M. Farese, Thomas J. MacVittie

      Pages 185-207

4. Use of Hematopoietic Growth Factors in Oncology

   1. Front Matter

      Pages 209-209

      PDF

   2. Commentary on the ASCO and ESMO Evidence-Based Clinical Practice Guidelines for the Use of Hematopoietic Colony-Stimulating Factors

      • Richard M. Fox

      Pages 211-217

   3. Neutropenia and the Problem of Fever and Infection in Patients With Cancer

      • David C. Dale

      Pages 219-233

   4. Thrombocytopenia and Platelet Transfusions in Patients With Cancer

      • Lawrence T. Goodnough

      Pages 235-247

   5. Hematopoietic Growth Factors in Lung Cancer

      • Johan F. Vansteenkiste, Christophe A. Dooms

      Pages 249-274

   6. Role of Hematopoietic Growth Factors As Adjuncts to the Treatment of Hodgkin’s and Non-Hodgkin’s Lymphomas

      • Marcie R. Tomblyn, Jane N. Winter

      Pages 275-284

   7. Use of Granulocyte Growth Factors in Breast Cancer

      • Eric D. Mininberg, Frankie Ann Holmes

      Pages 285-309

   8. Role of Cytokines in the Management of Chronic Lymphocytic Leukemia

      • Carol Ann Long

      Pages 311-332

Whether to promote platelet recovery or to ameliorate the complications of cancer and the side effects of chemotherapy, hematopoietic growth factors (HGFs) now account for more than $5 billion per year of the US health care budget. In Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics, leading oncologists, hematologists, and nephrologists comprehensively review the role of HGFs in clinical practice, explain the molecular basis of their effects, and consider potential future developments. The authors focus on the use of HGFs in oncology, describing their cutting-edge application to patients with lung cancer, Hodgkin's and non-Hodgkin's lymphoma, breast cancer, chronic lymphocytic leukemia, AIDS-related malignancies, myelodysplastic syndromes, and aplastic anemias. Among the HGFs described are granulocyte colony-stimulating factor, erythropoietc factors, thrombopoietic factors, and stem-cell factor and its receptor, c-kit. To complete their survey, the contributors also consider the safety and economic implications of HGFs and the future potential for HGF antagonists in oncology.
Comprehensive and up-to-date, Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Practice offers an integrated survey of the role of HGFs in treating and preventing anemia, neutropenia, and thrombocytopenia in patients with malignant and nonmalignant diseases, along with fresh insights into drug development and how basic discoveries in this area can be optimally translated into clinical benefit.

• anemia
• cell
• cytokines
• leukemia
• lymphoma
• pathology
• pharmacology
• stem cell

"Comprehensive and up-to-date...offers an integrated survey of the role of HGFs in treating and preventing anemia, neutropenia, and thrombotopenia in patients wit malignant diseases, along with fresh insights into drug development and how basic discoveries in this area can be optimally translated into clinical benefit." - Tumori

• Amgen, Australia, Pty. Ltd., Monash University, Australia

  George Morstyn

• Amgen Inc., Thousand Oaks, USA

  MaryAnn Foote

• Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Melbourne, Australia

  Graham J. Lieschke

Policies and ethics